|
See related Integrilin information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
DKSH |
|
Contents |
Eptifibatide |
|
Indications |
Prevention of platelet aggregation in patients w/ unstable angina or non-Q-wave MI. Adjunct to percutaneous transluminal coronary angioplasty (PTCA); prevention of abrupt closure of treated coronary vessel & related acute ischemic cardiac complications. |
|
Dosage |
Unstable angina or non-Q-wave MI 180 mcg/kg IV bolus, followed by 2 mcg/kg/min continuous IV for up to 72 hr or more. If PTCA is performed during therapy, continue infusion for 20-24 hr post-PTCA. Max duration of therapy: 96 hr. Patients undergoing PTCA 180 mcg/kg IV bolus immediately prior to PTCA, followed by continuous infusion of 2 mcg/kg/min for at least 18-24 hr post PCI. |
|
Contraindications |
GI bleeding, gross genitourinary bleeding or other active abnormal bleeding w/in previous 30 days of treatment. History of stroke, hemorrhagic stroke or diathesis, major surgery w/in past 6 wk. Thrombocytopenia, prothrombin time (INR ≥2), severe HTN. Lactation. |
|
Special Precautions |
Hepatic impairment, renal failure. Pregnancy. Childn. |
|
Adverse Drug Reactions |
Bleeding, CV effects.
View ADR Monitoring Form |
|
Drug Interactions |
Furosemide, streptokinase, heparin, oral anticoagulants, dipyridamole.
View more drug interactions with Integrilin |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Integrilin injection |
|
Integrilin 2 mg/1 mL x 10 mL |
|
|
Integrilin infusion |
|
Integrilin 0.75 mg/1 mL x 100 mL |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
DKSH |
|
|
|
|
